Physician profile
Anna Rothstein
NPI 1679222830
$2,016.94
in general payments reported to CMS, 2019-2025
15 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $126 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.29 |
| Education | $184.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $553.52 | 2024-2025 | Tezspire, Breztri, Fasenra |
| Genzyme Corporation | $259.94 | 2025 | |
| Csl Behring | $224.80 | 2025 | Andembry, Hizentra |
| Amgen INC. | $172.66 | 2024-2025 | Actimmune, Tezspire |
| Regeneron Healthcare Solutions, INC. | $166.41 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $151.53 | 2025 | Takhzyro, Glassia, Hyqvia |
| Galderma Laboratories, L.P. | $114.29 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $94.11 | 2024-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Pfizer INC. | $69.02 | 2024-2025 | |
| Invivyd INC | $48.34 | 2025 | Pemgarda |
| Octapharma USA, INC. | $20.02 | 2025 | Panzyga |
| Blueprint Medicines Corporation | $19.57 | 2024 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $17.04 | 2024 | Eliquis |
| Grifols USA, LLC | $15.70 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.